Shots:

• The approval is based on P-III KATHERINE study assessing Kadcyla vs Herceptin as adjuvant therapy in people with HER2+ eBC with pathological residual invasive disease in the breast and/or axillary lymph nodes following neoadjuvant taxane and Herceptin-based treatment
• The P-III KATHERINE study results: reduction in the risk of residual invasive BC recurrence or death from any cause; @3yrs. reoccurrence of BC (88.3% vs 77%); patients with the residual invasive disease after neoadjuvant treatment have a worse prognosis than those with no detectable disease
• Kadcyla (trastuzumab emtansine) is an ADC- a combination of trastuzumab and DM1- delivering CT directly to HER2+ cancer cells. It has received approval in 104 countries including the US & EU for HER2+ m-breast cancer and is developed using ADC technology licensed from ImmunoGen

Click here to­ read full press release/ article 

Ref: Newswire Canada | Image: Roche